A prospective, non-randomized, non-controlled clinical trial in a cohort of HD patients suggested a decrease in inflammatory and OS biomarkers after NAC administration, including high-sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) [95], which have been repeatedly reported to be indicators of CV disease in CKD. The gene discussed is IL6; the disease is Huntington disease.